|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2004-5-12
|
|
pubmed:abstractText |
In the present study, we have examined the kinetics and magnitude of expression of the CD28 and CD152 molecules on unstimulated and anti-CD3+rIL-2-stimulated peripheral blood CD4+ and CD8+ T cells in patients with chronic lymphocytic leukaemia (B-CLL) and controls. The mean percentages of both CD3+/CD4+/CD28+ and CD3+/CD8+/CD28+ cells were significantly lower in B-CLL than in controls before culture, decreased rapidly, reaching their lowest levels between 24 and 48 h, and returned to basal levels after 72 h of culture. In controls, the lowest proportions of CD3+/CD4+/CD28+ and CD3+/CD8+/CD28+ cells were found after 24 h and returned to prestimulation levels after 48 h of stimulation. We observed significantly higher proportions of unstimulated CD3+/CD4+/CD152+ and CD3+/CD8+/CD152+ cells in B-CLL patients than in controls. The highest percentages of CD3+/CD4+/CD152+ and CD3+/CD8+/CD152+ cells were observed in controls after 72 h, and in B-CLL patients after 24 h, and remained statistically higher after 48, 72 and 96 h of stimulation. CD152 molecule expression returned to prestimulation levels after 96 h of culture in controls, and after 120 h in B-CLL patients. The abnormal kinetics and levels of CD28 and CD152 expression on T cells in B-CLL may lead to a state of hyporesponsiveness or anergy and could be one of the mechanisms of immune deficiency in this disease.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-10330272,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-10421790,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-10881170,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-10903737,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-11298591,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-11544310,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-12010662,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-12100149,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-6408172,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-7481803,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-7534620,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-7682233,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-7882171,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-7909242,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-7999409,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-8381831,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-8397258,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-8642868,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-8648099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-8676074,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-8676075,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-8691122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-9164923,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-9551948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-9593474,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-9815262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15138491-9856951
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
17
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2042-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15138491-Adult,
pubmed-meshheading:15138491-Aged,
pubmed-meshheading:15138491-Aged, 80 and over,
pubmed-meshheading:15138491-Antigens, CD,
pubmed-meshheading:15138491-Antigens, CD28,
pubmed-meshheading:15138491-Antigens, Differentiation,
pubmed-meshheading:15138491-CTLA-4 Antigen,
pubmed-meshheading:15138491-Case-Control Studies,
pubmed-meshheading:15138491-Down-Regulation,
pubmed-meshheading:15138491-Female,
pubmed-meshheading:15138491-Flow Cytometry,
pubmed-meshheading:15138491-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:15138491-Humans,
pubmed-meshheading:15138491-Kinetics,
pubmed-meshheading:15138491-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:15138491-Male,
pubmed-meshheading:15138491-Middle Aged,
pubmed-meshheading:15138491-T-Lymphocytes
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia.
|
|
pubmed:affiliation |
Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R Weigla 12, 53-114 Wroclaw, Poland. frydecka@hemat.am.wroc.pl
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
